ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen and BCG alone.

老虎证券2026/03/26 11:56

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Banco da Amazônia 1S26 net profit drops 38.6% to R$ 353.1 million; revenue rises 15.4% to R$ 3.47 billion

Reuters•2026/08/29 02:47

Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred

Cointime•2026/08/29 02:41

Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)

A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.

智通财经•2026/08/29 02:27

Zacatecas Silver closes second tranche of private placement, raises $1.02 million at $0.07 per unit

Reuters•2026/08/29 02:08